ORIG3N, Inc. opens new laboratory and headquarters in Boston’s Seaport District
BOSTON — ORIG3N, Inc., a pioneer in the field of regenerative medicine, recently announced the formal opening of its new headquarters and laboratory in Boston’s Seaport District, at 27 Drydock Avenue within the Innovation and Design Building.
ORIG3N’s new expanded facility will provide state-of-the-art functionality to sustain collaborative research programs that support ORIG3N’s cellular models called LifeSystems, as well as the company’s product development and commercial activities.
The company says, “Our science is based on Nobel Prize-winning regenerative medicine technology, and our approach will replace the trial-and-error guesswork of diagnosing and treating disease. We’ve established the world’s largest uniformly consented cell repository to better understand the cellular and molecular foundations of disease. The cells are ever-renewing and give rise to a living database of humanity we call LifeCapsule.”
Founded in 2014 by serial entrepreneurs Robin Y. Smith, CEO and Kate Blanchard, COO, ORIG3N uses iPSC technology to accelerate the future of medicine, including the pace of drug development, to overcome the trial-and-error approach common today. ORIG3N is the only biotechnology company that is crowdsourcing blood samples creating a new approach to the understanding and treatment of a variety of diseases.
ORIG3N builds and maintains the world’s largest crowdsourced biorepository of induced pluripotent stem cells (iPSCs) called LifeCapsule. The new facility will help accelerate the next stage of evolution with iPSC technology.
Read more at BioSpace.
Photo courtesy of ORIG3N